Fungal Infections Potentiated by Biologics

Matthew R. Davis, George R. Thompson, Thomas F. Patterson

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations


Biologic therapies including monoclonal antibodies, tyrosine kinase inhibitors, and other agents represent a notable expansion in the pharmacotherapy armamentarium in treatment of a variety of diseases. Many of these therapies possess direct or indirect immunosuppressive and immunomodulatory effects, which have been associated with bacterial, viral, and fungal opportunistic infections. Careful screening of baseline risk factors before initiation, targeted preventive measures, and vigilant monitoring while on active biologic therapy mitigate these risks as use of biologics becomes more commonplace. This review compiles reported evidence of fungal infections associated with these agents with a focus on the tumor necrosis factor-α inhibitor class.

Original languageEnglish (US)
Pages (from-to)389-411
Number of pages23
JournalInfectious disease clinics of North America
Issue number2
StatePublished - Jun 2020


  • Biologic
  • Fungal infections
  • Monoclonal antibodies
  • TNF-α inhibitors
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases


Dive into the research topics of 'Fungal Infections Potentiated by Biologics'. Together they form a unique fingerprint.

Cite this